spacer
home > ict > winter 2009 > strategic planning
PUBLICATIONS
International Clinical Trials

Strategic Planning

The pharmaceutical industry is experiencing tough times, facing both economic and regulatory pressures, with increasing demands for improved safety data and comparative efficacy studies, as well as late-stage pipeline failures and non-approvals by US and EU regulatory agencies. However, pharma has a wide variety of R&D strategies at its disposal to develop drug candidates faster and more efficiently. These can be implemented in isolation, but work more effectively in combination so as to optimise the linical trial process and increase the chance of clinical, and ultimately commercial, success. However, without efficient management and communication, the speed to market of a novel drug is likely to suffer.

CURRENT PROBLEMS WITH PHARMA R&D

In the increasingly competitive and cost-conscious pharmaceutical environment, it is important that pharma companies develop their pipeline products as quickly and cheaply as possible, while ensuring that they receive marketing approval as well as authorisation from the relevant reimbursement agencies. Failure to do so can have a significant economic impact and lead to company restructuring in order to balance the financial loss of drugs failing to reach the market (1).

During 2008, the number of drugs in Phase I clinical development was on the rise, but at the same time clinical trial success rates and the approval rate for new molecular entities (NMEs) were comparably low. In 2007, the FDA approved only 18 new drugs, the lowest number in 24 years (2). The number approved in 2008 was little better at 24 new approvals (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Alistair Sinclair is a Senior Analyst in the Strategic Intelligence team at Datamonitor. After joining in 2003, he worked for three years in the Central Nervous System Healthcare team, producing a number of market analysis reports, focusing particularly on psychiatry drug markets. Alistair moved to the Strategic Intelligence team in 2006, and has since produced reports on a wide variety of strategic issues including lifecycle management, corporate strategies, pricing and reimbursement, sales and marketing, R&D and the emerging markets. Alistair holds a BSc from the University of Edinburgh in Medical Microbiology, and an MSc from UCL and KCMC University, Tanzania. He has also worked at the Health Protection Agency, and has published a number of papers from his research. Email: asinclair@datamonitor.com

 

spacer
Alistair Sinclair
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the 11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement